Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 1364-1369

  Wong, L ^b,c   See, H T ^b   Khoo Tan, H S ^a   Low, J S ^a   Ng, W T ^b   Low, J J ^a  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cisplatin; Ifosfamide; MMMT uterus; Radiotherapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG METASTASIS; MIXED MULLERIAN TUMOR; PLEURA EFFUSION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; UTERUS TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; HUMANS; HYSTERECTOMY; IFOSFAMIDE; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 33745058649     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00560.x     Document Type: Article

References (37)

1. Major FJ Blessing JA Silverberg SG Morrow CP Creaseman WT Currie JL. Prognostic factors in early stage uterine sarcoma: a Gynecologic Oncology Group Study. Cancer 1993 71 ( Suppl. 4 1702 9.
2. Barwick KW LiVolski VA. Malignant mixed mullerian tumors of the uterus. A clinicopathologic assessment of 34 cases. Am J Surg Pathol 1979 3: 125 35.
3. Williamson EO Christopherson WM. Malignant mixed mullerian tumors of the uterus. Cancer 1972 29: 585 92.
4. Chuang JT Van Velden DJJ Graham JB. Carcinosarcoma and mixed mesodermal tumors of the uterine corpus. Obstet Gynecol 1970 35: 769 80.
5. Hacker NF. Uterine cancer. In: Berek JS Hacker NF, eds. Practical gynecologic oncology, 2nd edn. Baltimore, MD: Williams & Wilkins, 1994: 317 9.
6. Nielsen SN Podratz KC Scheithauer BW O'Brien PC. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol 1989 34: 372 8.
7. Dinh TV Slavin RE Bhagavan BS et al. Mixed mullerian tumors of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 1986 6: 417 24.
8. Schweizer W Demopoulos R Beller U et al. Prognostic factors for malignant mixed mullerian tumors of the uterus. Int J Gynecol Pathol 1990 9: 129 36.
9. Gerszten K Faul C Kounelis S Huang Q Kelley J Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998 68: 8 13.
10. Hornback NB Omura G Major FG. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986 12: 2127 30.
11. Manolitsas TP Wain GV Williams KE Friedlander M Hacker NF. Multimodality therapy for patients with clinical stage I and II malignant mixed mullerian tumors of the uterus. Cancer 2001 91: 1437 43.
12. Baggish MS. Mesenchynal tumors of the uterus. Clin Obstet Gynecol 1974 17: 51 86.
13. Rose PG Piver MS Tsukada Y Lau T. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer 1989 63: 935 8.
14. Norris HJ Roth E Taylor HB. Mesenchymal tumors of the uterus II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol 1966 28: 57 63.
15. Krupp PJ Sternberg WH Clark WH St Romain MJ Jr. Smith RC. Malignant mixed mullerian neoplasms (mixed mesodermal tumors). Am J Obstet Gynecol 1961 81: 959 69.
16. Kohorn EI Schwartz PE Chambers JT. Adjuvant therapy in mixed mullerian tumors of the uterus. Gynecol Oncol 1986 23: 212 21.
17. Larson B Silfversward B Nilsson B. Mixed mullerian tumors of the uterus - prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 1990 17: 123 32.
18. Knocke TH Weitmann HD Kucera H. Results of primary and adjuvant radiotherapy in the treatment of mixed mullerian tumors of the corpus uteri. Gynecol Oncol 1999 73: 389 95.
19. Covens AL Nisker JA Chapman WB Allan HH. Uterine sarcoma: an analysis of 74 cases. Am J Obstet Gynecol 1987 156: 370 4.
20. Callister M Ramondetta LD Jhingran A Burke TW Eifel PJ. Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004 58: 786 96.
21. Omura GA Blessing JA Major F Lifshitz S Ehrlich CE Mangan C. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1985 3: 1240 5.
22. Spanos WJ Wharton JT Gomez L Fletcher GH Oswald MJ. Malignant mixed mullerian tumors of the uterus. Cancer 1984 53: 311 6.
23. Mccluggage WG. Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002 12: 687 90.
24. Thigpen JT Blessing JA Orr JA Jr. DiSaia PJ. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mullerian mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 1986 70: 271 4.
25. Thigpen JT Blessing JA Beecham J Homesley H Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcoma: a Gynecologic Oncology Group study. J Clin Oncol 1991 9: 1962 6.
26. Sutton GP Blessing JA Rosenshein N Photopulos G DiSaia PJ. Phase II trial of ifosfamide with mesna in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1989 161: 309 12.
27. Sutton G Kauderer J Carson LF Lentz SS Whitney CW Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005 96: 630 4.
28. Sutton G Brunetto VL Kilgore L et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2000 79: 147 53.
29. Rijswijk REN Vermorken JB Reed N et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). Eur J Cancer 2003 39: 481 7.
30. Curtin JP Blessing JA Soper JT Degeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2001 83: 268 70.
31. Toyoshima M Akahira J Matsunaga G et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 2004 94: 774 8.
32. Muss HB Bundy BN Adcock L Beecham J. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecology Oncology Group. Am J Clin Oncol 1990 13: 32 4.
33. Fowler JM Blessing JA Burger RA., Malfetano JH. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2002 85: 311 4.
34. Thigpen JT Blessing JA Homesley HD Hacker N Curry SL. Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study. Am J Clin Oncol 1985 8: 350 2.
35. Miller DS Blessing JA Schilder J Munkarah A Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005 98: 217 21.
36. Peters WA Rivkin SE Smith MR Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed desodermal tumors. Gynecol Oncol 1989 34: 323 7.
37. Menczer J Levy T Piura B et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 2005 97: 166 70.